Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial

In this study (n=1,213), the addition of atezolizumab to platinum-based chemotherapy was associated with prolonged median progression-free survival (8.2 months [95% CI 6.5-8.3] v 6.3 months (6.2–7.0); HR 0.82, 0.70-0.96; p=0.007).

Source:

The Lancet